Loading
A phase 3 trial of Alpelisib and Fulvestrant in HR-positive / HER2-negative breast cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. is a phase 3 interventional study registered as NCT05038735 by Novartis Pharmaceuticals, with 210 participants enrolled, started 2021-12-17 and due to reach its primary completion in 2027-01-28. Interventions recorded: Alpelisib, Fulvestrant and Alpelisib-matching placebo.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, PI3K, AKT and mTOR inhibitors, HR-positive metastatic breast cancer after CDK4/6 inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Small-molecule kinase inhibitors and the tag pipeline.